Prevalence of high-risk human papilloma virus in women with high-grade squamous cell intraepithelial lesions in Botswana using Abbott RealTime HPV assay.
Adult
Alphapapillomavirus
/ classification
Biopsy
Botswana
Carcinoma, Squamous Cell
/ pathology
Disease Progression
Female
Genotyping Techniques
/ methods
Humans
Papillomavirus Infections
/ diagnosis
Paraffin Embedding
Prevalence
Prognosis
Squamous Intraepithelial Lesions of the Cervix
/ pathology
Tissue Fixation
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
04
2018
accepted:
10
01
2019
entrez:
31
1
2019
pubmed:
31
1
2019
medline:
28
10
2019
Statut:
epublish
Résumé
High-risk human papillomavirus (HR-HPV) has been demonstrated to be the necessary cause of cervical carcinoma. High-risk HPV detection has a prognostic significance for the women who are at increased risk of disease progression. HPV genotyping in cervical cancer precursor lesions is crucial for prevention and management of cervical cancer. This study was designed to investigate the distribution of HR-HPV genotypes among a group of patients with high-grade squamous intraepithelial lesions and higher, of the cervix, in Botswana. 185-archived residual formalin-fixed paraffin-embedded cervical biopsies collected between the years, 2006 and 2008 were studied. These tissues were diagnosed with HSIL (n = 146) and squamous cell carcinoma (n = 39). DNA was extracted using the Abbott m2000 analyser (Abbott Laboratories, Illinois) using reagents provided by the manufacturer. HPV genotyping was done using the Abbott RealTime HR-HPV PCR, which qualitatively detects 14 HR-HPV (reported as HPV 16, 18 & Other HR-HPV). DNA was successfully extracted from 162/185 (87.6%) tissues as indicated by a positive β-globin test. 132/162 (82%) tested positive for HR-HPV The HPV 16 prevalence was 50% (66/132), HPV 18 at 15.2% (20/132) and other Group 1 HR-HPV plus HPV 66 and 68 had a prevalence of 56.1% (74/132). Other HR-HPV types were common in HSIL than in carcinoma, while HPV 16 was more prevalent in carcinomas than other HR-HPV genotypes. In this study, HPV 16 and other HR-HPV genotypes were commonly associated with HSIL but HPV 18 was uncommon among Botswana women. Our data highlights the need for multivalent HPV vaccines with cross coverage for other high risk HPV other than HPV 16 and 18.
Sections du résumé
BACKGROUND
High-risk human papillomavirus (HR-HPV) has been demonstrated to be the necessary cause of cervical carcinoma. High-risk HPV detection has a prognostic significance for the women who are at increased risk of disease progression. HPV genotyping in cervical cancer precursor lesions is crucial for prevention and management of cervical cancer. This study was designed to investigate the distribution of HR-HPV genotypes among a group of patients with high-grade squamous intraepithelial lesions and higher, of the cervix, in Botswana.
MATERIALS AND METHODS
185-archived residual formalin-fixed paraffin-embedded cervical biopsies collected between the years, 2006 and 2008 were studied. These tissues were diagnosed with HSIL (n = 146) and squamous cell carcinoma (n = 39). DNA was extracted using the Abbott m2000 analyser (Abbott Laboratories, Illinois) using reagents provided by the manufacturer. HPV genotyping was done using the Abbott RealTime HR-HPV PCR, which qualitatively detects 14 HR-HPV (reported as HPV 16, 18 & Other HR-HPV).
RESULTS
DNA was successfully extracted from 162/185 (87.6%) tissues as indicated by a positive β-globin test. 132/162 (82%) tested positive for HR-HPV The HPV 16 prevalence was 50% (66/132), HPV 18 at 15.2% (20/132) and other Group 1 HR-HPV plus HPV 66 and 68 had a prevalence of 56.1% (74/132). Other HR-HPV types were common in HSIL than in carcinoma, while HPV 16 was more prevalent in carcinomas than other HR-HPV genotypes.
CONCLUSION
In this study, HPV 16 and other HR-HPV genotypes were commonly associated with HSIL but HPV 18 was uncommon among Botswana women. Our data highlights the need for multivalent HPV vaccines with cross coverage for other high risk HPV other than HPV 16 and 18.
Identifiants
pubmed: 30699172
doi: 10.1371/journal.pone.0211260
pii: PONE-D-18-11661
pmc: PMC6353155
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211260Subventions
Organisme : FIC NIH HHS
ID : D43 TW010543
Pays : United States
Organisme : Wellcome Trust
ID : 107752/Z/15/Z
Pays : United Kingdom
Déclaration de conflit d'intérêts
PR received donations of testing kits from Abbott Laboratories in South Africa. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Références
Lancet. 2010 Oct 2;376(9747):1186-93
pubmed: 20709386
J Med Virol. 2011 Oct;83(10):1689-95
pubmed: 21837784
Lancet. 1995 Apr 22;345(8956):1051-2
pubmed: 7723522
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Gynecol Oncol. 2006 Oct;103(1):12-7
pubmed: 16934860
Infect Agent Cancer. 2011 Nov 14;6(1):20
pubmed: 22081870
J Int AIDS Soc. 2013 Feb 14;16:18023
pubmed: 23406965
Acta Dermatovenerol Alp Pannonica Adriat. 2013;22(2):43-7
pubmed: 23836358
Virol J. 2017 Dec 21;14(1):241
pubmed: 29268766
Front Oncol. 2015 Nov 03;5:239
pubmed: 26579491
Lancet Oncol. 2011 Sep;12(9):880-90
pubmed: 21865084
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Gynecol Oncol. 2006 Oct;103(1):21-4
pubmed: 16919714
Int J Gynecol Pathol. 2011 Nov;30(6):591-6
pubmed: 21979597
Curr Probl Dermatol. 2014;45:75-91
pubmed: 24643179
Lancet Infect Dis. 2009 Jun;9(6):347-56
pubmed: 19467474
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
J Clin Microbiol. 2011 Apr;49(4):1446-51
pubmed: 21325553
Virol J. 2014 Jan 15;11:5
pubmed: 24433568
PLoS One. 2015 Aug 12;10(8):e0135602
pubmed: 26267867
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
Int J Gynecol Pathol. 1992 Jul;11(3):197-203
pubmed: 1328077
Cancer Cytopathol. 2015 May;123(5):271-81
pubmed: 25931431
Drug Healthc Patient Saf. 2012;4:167-72
pubmed: 23152707
BMC Infect Dis. 2007 Jul 16;7:77
pubmed: 17634108
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Int J Cancer. 2012 Nov 15;131(10):2349-59
pubmed: 22323075
Trop Med Int Health. 2012 Dec;17(12):1432-40
pubmed: 23107344
Clin Microbiol Rev. 2003 Jan;16(1):1-17
pubmed: 12525422
J Med Virol. 2011 Jan;83(1):119-26
pubmed: 21108348
J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):308-13
pubmed: 22134146
Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S209-12
pubmed: 16202445
Emerg Infect Dis. 2015 Sep;21(9):1557-61
pubmed: 26291379